ClinicalTrials.gg
RecruitingNCT07170917BRIGHTENUpdated Oct 14, 2026

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

A Phase 2 interventional study of Brivekimig and Placebo in Hidradenitis Suppurativa, sponsored by Sanofi. Recruiting at 85 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 14, 202645 sites added39 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.

Planned enrollment
37th of 139
208 · median 45
Started
2025
with 24 others
Phase 2
61 of 161
11 open now
Primary completion
2027-02
later than 20 of 54 live
Registered
141st of 161
by date

Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 37th largest by planned enrollment of the 139 interventional ones that give a count, is one of 25 that started in 2025, is one of 61 in phase 2, reaches primary completion later than 20 of the 54 other live ones, and was the 141st registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Hidradenitis Suppurativa with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa.

The purpose of the main study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe HS.

Study details include:

The study duration (per participant) will be up to approximately 164 weeks for participants transitioning into the long-term extension (LTE) period and will be up to approximately 60 weeks for participants not transitioning into the LTE period.

The randomized treatment duration will be up to approximately 152 weeks

03

Conditions studied

  • Hidradenitis Suppurativa
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months prior to Baseline
  • Participants must have HS lesions present in at least 2 distinct anatomic areas (eg, left and right axilla; or left axilla and left inguinocrural fold), one of which must be Hurley Stage II or Hurley Stage III.
  • Participant must have had an inadequate response to a trial of an oral antibiotic for treatment of HS, exhibited recurrence after discontinuation of antibiotics, demonstrated intolerance to antibiotics, or has a to oral antibiotics for treatment of their HS as assessed by the Investigator through participant interview and review of medical history.
  • Participants must be either biologic-naive or biologic-experienced.
  • Participant must have a total abscess and inflammatory nodule (AN) count of ≥5 at the Baseline visit.
  • Participant must have a draining tunnel count of ≤20 at the Baseline visit.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with assessment of HS
  • History of recurrent or recent serious infection
  • Known history of significant
  • History of solid organ transplant or stem cell transplant
  • History of splenectomy
  • History of moderate to severe congestive heart failure.
  • History of demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease
  • Participants with a history of or lymphoproliferative disease other than adequately treated or nonmetastatic squamous cell carcinoma of the skin that was excised and completely cured or nonmetastatic basal cell carcinoma of the skin that was excised and completely cured
  • History of any other condition which, in the opinion of the Investigator, would put the participant at risk by participation in the protocol
  • Active suicidality and therefore significant suicide risk, as judged by the Investigator
  • A history of an Adverse Event (AE) attributed to or related to anti-TNF therapy (examples include, but are not limited, to serum sickness or anaphylaxis) for an HS or non-HS indication that would contraindicate readministration of an anti-TNF class therapy
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
  • History (within last 2 years prior to Baseline visit) of prescription drug or substance abuse, including alcohol, considered significant by the Investigator

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
208 participants (estimated)

Study arms

  • Experimental
    Brivekimig dose regimen A

    Participants will receive Brivekimig dose regimen A.

    Drug: Brivekimig

  • Experimental
    Brivekimig dose regimen B

    Participants will receive Brivekimig dose regimen B.

    Drug: Brivekimig

  • Experimental
    Brivekimig dose regimen C

    Participants will receive Brivekimig dose regimen C.

    Drug: Brivekimig

  • Placebo comparator
    Placebo

    Participants will receive Brivekimig matching placebo.

    Drug: Placebo

Interventions

  • * Pharmaceutical form: Solution for injection in vial * Route of administration: Subcutaneous injection

    Also known as: SAR442970

  • DrugPlacebo

    * Pharmaceutical form: Solution for injection in vial * Route of administration: Subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)

    Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) is defined as ≥75% reduction from Baseline in the total abscess and inflammatory nodule \[AN\] count, with no increase from Baseline in abscess or draining tunnel count.

    Time frame: Up to Week 16

Secondary outcomes

  1. Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)

    Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) is defined as ≥50% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining tunnel count.

    Time frame: Up to Week 16

  2. Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 90 (HiSCR90)

    Hidradenitis Suppurativa Clinical Response 90 (HiSCR90) is defined as ≥90% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining tunnel count.

    Time frame: Up to Week 16

  3. Change from Baseline in draining tunnel count at Week 16.

    Time frame: From Baseline to Week 16

  4. Change from Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) at Week 16

    The determination of IHS4 requires counting the inflammatory nodules, abscesses and draining tunnels and multiplying each by a specific coefficient. A high score signifies severe disease.

    Time frame: From Baseline to Week 16

  5. Percentage of participants achieving response on the Hidradenitis Suppurativa Skin Pain Numeric Rating Scale from the HS Symptom Assessment Questionnaire (HS-SAQ skin pain NRS) at week 8

    The Hidradenitis Suppurativa Symptom Assessment Questionnaire (HS-SAQ) is a 7-item scale comprising unidimensional numeric rating scale (NRS) items assessing symptoms of HS. The HS-SAQ Skin Pain is based on worst skin pain in a 24-hour recall period (daily assessment is averaged over 7-day period). HS-SAQ skin pain NRS response is defined as ≥3-unit reduction from baseline in the weekly average of daily HS-SAQ Skin Pain NRS.

    Time frame: From Baseline to Week 8

  6. Change from Baseline in Hidradenitis Suppurativa Quality of Life (HiSQOL) total score at Week 16.

    The Hidradenitis Suppurativa Quality of Life is a 17-item content-validated questionnaire with a 7-day recall period. It is scored by summing items to create a total score (0 to 68) with higher score indicating more severe impact on QoL.

    Time frame: From Baseline to Week 16

  7. Change from Baseline in Dermatology Life Quality Index (DLQI) total score at Week 16.

    The Dermatology Life Quality Index (DLQI) is a 10-item dermatology specific health related quality of life (HRQoL) instrument. Total score ranges from 0 to 30, with higher scores indicating greater detrimental impact on QoL.

    Time frame: From Baseline to Week 16

  8. Number of participants with treatment-emergent adverse events (TEAE), serious adverse events (SAE) and laboratory anomalies.

    Time frame: Up to End of Study (approximately 164 weeks)

  9. Serum brivekimig concentration throughout the study.

    Time frame: From Baseline to Week 160

  10. Incidence of treatment-emergent (TE) anti-drug antibody responses.

    Time frame: Up to End of Study (approximately 164 weeks)

07

Study locations

77 of 85 sites recruiting
  • Medical Dermatology Specialists- Site Number : 8400019
    Phoenix, Arizona 85006, United States
    Recruiting
  • Mayo Clinic in Arizona - Scottsdale- Site Number : 8400014
    Scottsdale, Arizona 85259, United States
    Recruiting
  • Northridge Clinical Trials - Northridge- Site Number : 8400005
    Northridge, California 91325, United States
    Recruiting
  • Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8400001
    Fort Myers, Florida 33919, United States
    Recruiting
  • FXM Clinical Research - Miami- Site Number : 8400017
    Miami, Florida 33175, United States
    Recruiting
  • FXM Clinical Research - Miramar- Site Number : 8400004
    Miramar, Florida 33027, United States
    Recruiting
  • Advanced Medical Research - Atlanta- Site Number : 8400011
    Atlanta, Georgia 30342, United States
    Recruiting
  • Georgia Skin & Cancer Clinic- Site Number : 8400009
    Savannah, Georgia 31419, United States
    Recruiting
  • The Iowa Clinic West Des Moines Campus- Site Number : 8400007
    West Des Moines, Iowa 50266, United States
    Recruiting
  • Louisiana Dermatology Associates- Site Number : 8400006
    Baton Rouge, Louisiana 70809, United States
    Recruiting
  • Washington University- Site Number : 8400010
    St Louis, Missouri 63110, United States
    Recruiting
  • JDR Dermatology Research- Site Number : 8400012
    Las Vegas, Nevada 89145, United States
    Recruiting
  • Icahn School of Medicine at Mount Sinai- Site Number : 8400021
    New York, New York 10029, United States
    Recruiting
  • University of North Carolina at Chapel Hill- Site Number : 8400025
    Chapel Hill, North Carolina 27514, United States
    Recruiting
  • Clinical Partners- Site Number : 8400002
    Johnston, Rhode Island 02919, United States
    Recruiting
  • AMR Clinical South Strand, South Carolina- Site Number : 8400018
    Myrtle Beach, South Carolina 29588, United States
    Recruiting
  • Ut Southwestern Medical Center, Department Of Dermatology- Site Number : 8400022
    Dallas, Texas 75235, United States
    Recruiting
  • Investigational Site Number : 0360003
    Liverpool, New South Wales 2170, Australia
    Recruiting
  • Investigational Site Number : 0360002
    Melbourne, Victoria 3004, Australia
    Recruiting
  • Investigational Site Number : 1240008
    Edmonton, Alberta T6H 4J8, Canada
    Recruiting
  • Investigational Site Number : 1240007
    Sherwood Park, Alberta T8H 0P1, Canada
    Recruiting
  • Investigational Site Number : 1240003
    Kelowna, British Columbia V1W 4V5, Canada
    Recruiting
  • Investigational Site Number : 1240001
    Hamilton, Ontario L8L 3C3, Canada
    Recruiting
  • Investigational Site Number : 1240009
    Toronto, Ontario M4E 1R7, Canada
    Recruiting
  • Investigational Site Number : 1240005
    Québec, Quebec G1W 4R4, Canada
    Recruiting
  • Investigational Site Number : 1520004
    Talcahuano, Biobio 2687000, Chile
    Recruiting
  • Investigational Site Number : 1520003
    Santiago, Reg Metropolitana de Santiago 7580206, Chile
    Recruiting
  • Investigational Site Number : 1520002
    Santiago, Reg Metropolitana de Santiago 7640881, Chile
    Recruiting
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 8380465, Chile
    Recruiting
  • Investigational Site Number : 1520005
    Santiago, Reg Metropolitana de Santiago 8420383, Chile
    Recruiting
  • Investigational Site Number : 1560002
    Chengdu, 610041, China
    Recruiting
  • Investigational Site Number : 1560001
    Guangzhou, 510018, China
    Recruiting
  • Investigational Site Number : 1560004
    Shanghai, 200040, China
    Recruiting
  • Investigational Site Number : 1560005
    Ürümqi, 830001, China
    Recruiting
  • Investigational Site Number : 2030002
    Ostrava, 702 00, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Investigational Site Number : 2030003
    Ostrava, 708 52, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Investigational Site Number : 2030001
    Prague, 110 00, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Investigational Site Number : 2030004
    Prague, 150 06, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Investigational Site Number : 2500001
    Antony, 92160, France
    Recruiting
  • Investigational Site Number : 2500004
    Bezannes, 51430, France
    Recruiting
  • Investigational Site Number : 2500003
    Bordeaux, 33000, France
    Recruiting
  • Investigational Site Number : 2500002
    Lyon, 69003, France
    Recruiting
  • Investigational Site Number : 2500006
    Saint-Priest-en-Jarez, 42270, France
    Recruiting
  • Investigational Site Number : 2500007
    Toulouse, 31059, France
    Recruiting
  • Investigational Site Number : 2760002
    Bochum, 44791, Germany
    Recruiting
  • Investigational Site Number : 2760008
    Bramsche, 49565, Germany
    Recruiting
  • Investigational Site Number : 2760003
    Frankfurt, 60590, Germany
    Recruiting
  • Investigational Site Number : 2760005
    Kiel, 24105, Germany
    Recruiting
  • Investigational Site Number : 2760004
    Mainz, 55131, Germany
    Recruiting
  • Investigational Site Number : 2760001
    Münster, 48149, Germany
    Recruiting
  • Investigational Site Number : 2760006
    Würzburg, 97080, Germany
    Recruiting
  • Investigational Site Number : 3000002
    Athens, 124 62, Greece
    Recruiting
  • Investigational Site Number : 3000001
    Athens, 16121, Greece
    Recruiting
  • Investigational Site Number : 3000005
    Athens, 16121, Greece
    Recruiting
  • Investigational Site Number : 3000004
    Thessaloniki, 564 29, Greece
    Recruiting
  • Investigational Site Number : 3480001
    Debrecen, 4032, Hungary
    Recruiting
  • Investigational Site Number : 3480003
    Pécs, 7632, Hungary
    Recruiting
  • Investigational Site Number : 3480004
    Székesfehérvár, 8000, Hungary
    Recruiting
  • Investigational Site Number : 3760003
    Haifa, 3109601, Israel
    Recruiting
  • Investigational Site Number : 3760002
    Jerusalem, 9112001, Israel
    Recruiting
  • Investigational Site Number : 3760001
    Tel Aviv, 6423906, Israel
    Recruiting
  • Investigational Site Number : 3800004
    Rome, Lazio 00144, Italy
    Recruiting
  • Investigational Site Number : 3800002
    Milan, Milano 20122, Italy
    Recruiting
  • Investigational Site Number : 3800005
    Rozzano, Milano 20089, Italy
    Recruiting
  • Investigational Site Number : 3800006
    Rome, Roma 00167, Italy
    Recruiting
  • Investigational Site Number : 3800001
    Catania, 95123, Italy
    Recruiting
  • Investigational Site Number : 3920003
    Nishinomiya, Hyōgo 663-8186, Japan
    Recruiting
  • Investigational Site Number : 3920002
    Nishihara, Okinawa 903-0215, Japan
    Recruiting
  • Investigational Site Number : 3920001
    Tokyo, 173-8610, Japan
    Recruiting
  • Investigational Site Number : 5280002
    Groningen, 9713 GR, Netherlands
    Recruiting
  • Investigational Site Number : 6160004
    Wroclaw, Lower Silesian Voivodeship 50-088, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Investigational Site Number : 6160001
    Wroclaw, Lower Silesian Voivodeship 50-566, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Investigational Site Number : 6160003
    Lodz, Lódzkie 90-265, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Investigational Site Number : 6160002
    Warsaw, Masovian Voivodeship 02-507, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Grupo Dermatologico de Carolina- Site Number : 8400023
    Carolina, 00985, Puerto Rico
    Recruiting
  • Investigational Site Number : 7240006
    Santiago de Compostela, A Coruña [La Coruña] 15706, Spain
    Recruiting
  • Investigational Site Number : 7240004
    Cadiz, Andalusia 11009, Spain
    Recruiting
  • Investigational Site Number : 7240003
    Las Palmas de Gran Canaria, Las Palmas 35010, Spain
    Recruiting
  • Investigational Site Number : 7240001
    Madrid, Madrid, Comunidad de 28046, Spain
    Recruiting
  • Investigational Site Number : 7240002
    Manises, Valencia 46940, Spain
    Recruiting
  • Investigational Site Number : 7240007
    Granada, 18014, Spain
    Recruiting
  • Investigational Site Number : 7240005
    Madrid, 28007, Spain
    Recruiting
  • Investigational Site Number : 7840001
    Abu Dhabi, United Arab Emirates
    Recruiting
  • Investigational Site Number : 8260008
    London, England E1 1BB, United Kingdom
    Recruiting
  • Investigational Site Number : 8260006
    Leeds, LS9 7TF, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Feb 2027, 15 months after the start.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 15 months is close to that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2025
First posted
Sep 12, 2025
StartActual
Nov 6, 2025
Primary completionEst.
Feb 9, 2027
CompletionEst.
Nov 23, 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
45 sites added, 39 sites removed
Show 45 added (6 United States, 6 Spain, 5 Chile, 4 Canada, 4 Czechia, 4 Italy, 4 Poland, 3 France, 3 Japan, 2 Australia, 2 Hungary, 2 Israel)
  • Medical Dermatology Specialists- Site Number : 8400019 · Phoenix, United States
  • Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8400001 · Fort Myers, United States
  • JDR Dermatology Research- Site Number : 8400012 · Las Vegas, United States
  • Icahn School of Medicine at Mount Sinai- Site Number : 8400021 · New York, United States
  • University of North Carolina at Chapel Hill- Site Number : 8400025 · Chapel Hill, United States
  • Ut Southwestern Medical Center, Department Of Dermatology- Site Number : 8400022 · Dallas, United States
  • Investigational Site Number : 0360003 · Liverpool, Australia
  • Investigational Site Number : 0360002 · Melbourne, Australia
  • Investigational Site Number : 1240007 · Sherwood Park, Canada
  • Investigational Site Number : 1240003 · Kelowna, Canada
  • Investigational Site Number : 1240001 · Hamilton, Canada
  • Investigational Site Number : 1240005 · Québec, Canada
  • Investigational Site Number : 1520004 · Talcahuano, Chile
  • Investigational Site Number : 1520003 · Santiago, Chile
  • Investigational Site Number : 1520002 · Santiago, Chile
  • Investigational Site Number : 1520001 · Santiago, Chile
  • Investigational Site Number : 1520005 · Santiago, Chile
  • Investigational Site Number : 2030002 · Ostrava, Czechia
  • Investigational Site Number : 2030003 · Ostrava, Czechia
  • Investigational Site Number : 2030001 · Prague, Czechia
  • Investigational Site Number : 2030004 · Prague, Czechia
  • Investigational Site Number : 2500001 · Antony, France
  • Investigational Site Number : 2500004 · Bezannes, France
  • Investigational Site Number : 2500007 · Toulouse, France
  • Investigational Site Number : 3480001 · Debrecen, Hungary
  • Investigational Site Number : 3480003 · Pécs, Hungary
  • Investigational Site Number : 3760002 · Jerusalem, Israel
  • Investigational Site Number : 3760001 · Tel Aviv, Israel
  • Investigational Site Number : 3800004 · Rome, Italy
  • Investigational Site Number : 3800002 · Milan, Italy
  • …and 15 more on the registry record
Show 39 removed
  • Medical Dermatology Specialists - Site Number: 8400019 · Phoenix, United States
  • JDR Dermatology Research - Site number: 8400012 · Las Vegas, United States
  • UT Southwestern Medical Center, Department of Dermatology- Site Number : 8400022 · Dallas, United States
  • Alpine Research Association- Site Number : 8400008 · Layton, United States
  • Investigational Site Number: 0360001 · Liverpool, Australia
  • Alfred Hospital - Site Number: 0360002 · Melbourne, Australia
  • Interior Dermatology Centre - Site Number: 1240003 · Kelowna, Canada
  • Lima's Excellence in Allergy and Dermatology Research (LEADER) Inc. · Hamilton, Canada
  • Investigational Site Number: 1240005 · Québec, Canada
  • Park Dermatology - Site number: 1240007 · Sherwood Park, Canada
  • Investigational Site Number: 1520003 · Santiago, Chile
  • Investigational Site Number: 1520002 · Santiago, Chile
  • Investigational Site Number: 1520001 · Santiago, Chile
  • Investigational Site Number: 1520005 · Santiago, Chile
  • Investigational Site Number: 2030002 · Ostrava, Czechia
  • Investigational Site Number: 2030003 · Ostrava, Czechia
  • Investigational Site Number: 2030001 · Prague, Czechia
  • Investigational Site Number: 2030004 · Prague, Czechia
  • Investigational Site Number: 2500001 · Antony, France
  • Investigational Site Number: 2500004 · Bezannes, France
  • Investigational Site Number: 2500007 · Toulouse, France
  • Site Number: 3480001 · Debrecen, Hungary
  • Investigational Site Number: 3480003 · Pécs, Hungary
  • Investigational Site Number: 3760002 · Jerusalem, Israel
  • Investigational Site Number: 3760001 · Tel Aviv, Israel
  • Investigational Site Number: 3800002 · Milan, Italy
  • Istituto Dermatologico San Gallicano, IRCCS - Site Number : 3800004 · Roma, Italy
  • Meiwa Hospital · Nishinomiya, Japan
  • University of the Ryukyus Hospital - Site Number: 3920002 · Nishihara, Japan
  • Nihon University Itabashi Hospital · Tokyo, Japan
  • …and 9 more on the registry record
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    45 sites added, 39 sites removed
    Show 45 added (6 United States, 6 Spain, 5 Chile, 4 Canada, 4 Czechia, 4 Italy, 4 Poland, 3 France, 3 Japan, 2 Australia, 2 Hungary, 2 Israel)
    • Medical Dermatology Specialists- Site Number : 8400019 · Phoenix, United States
    • Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8400001 · Fort Myers, United States
    • JDR Dermatology Research- Site Number : 8400012 · Las Vegas, United States
    • Icahn School of Medicine at Mount Sinai- Site Number : 8400021 · New York, United States
    • University of North Carolina at Chapel Hill- Site Number : 8400025 · Chapel Hill, United States
    • Ut Southwestern Medical Center, Department Of Dermatology- Site Number : 8400022 · Dallas, United States
    • Investigational Site Number : 0360003 · Liverpool, Australia
    • Investigational Site Number : 0360002 · Melbourne, Australia
    • Investigational Site Number : 1240007 · Sherwood Park, Canada
    • Investigational Site Number : 1240003 · Kelowna, Canada
    • Investigational Site Number : 1240001 · Hamilton, Canada
    • Investigational Site Number : 1240005 · Québec, Canada
    • Investigational Site Number : 1520004 · Talcahuano, Chile
    • Investigational Site Number : 1520003 · Santiago, Chile
    • Investigational Site Number : 1520002 · Santiago, Chile
    • Investigational Site Number : 1520001 · Santiago, Chile
    • Investigational Site Number : 1520005 · Santiago, Chile
    • Investigational Site Number : 2030002 · Ostrava, Czechia
    • Investigational Site Number : 2030003 · Ostrava, Czechia
    • Investigational Site Number : 2030001 · Prague, Czechia
    • Investigational Site Number : 2030004 · Prague, Czechia
    • Investigational Site Number : 2500001 · Antony, France
    • Investigational Site Number : 2500004 · Bezannes, France
    • Investigational Site Number : 2500007 · Toulouse, France
    • Investigational Site Number : 3480001 · Debrecen, Hungary
    • Investigational Site Number : 3480003 · Pécs, Hungary
    • Investigational Site Number : 3760002 · Jerusalem, Israel
    • Investigational Site Number : 3760001 · Tel Aviv, Israel
    • Investigational Site Number : 3800004 · Rome, Italy
    • Investigational Site Number : 3800002 · Milan, Italy
    • …and 15 more on the registry record
    Show 39 removed
    • Medical Dermatology Specialists - Site Number: 8400019 · Phoenix, United States
    • JDR Dermatology Research - Site number: 8400012 · Las Vegas, United States
    • UT Southwestern Medical Center, Department of Dermatology- Site Number : 8400022 · Dallas, United States
    • Alpine Research Association- Site Number : 8400008 · Layton, United States
    • Investigational Site Number: 0360001 · Liverpool, Australia
    • Alfred Hospital - Site Number: 0360002 · Melbourne, Australia
    • Interior Dermatology Centre - Site Number: 1240003 · Kelowna, Canada
    • Lima's Excellence in Allergy and Dermatology Research (LEADER) Inc. · Hamilton, Canada
    • Investigational Site Number: 1240005 · Québec, Canada
    • Park Dermatology - Site number: 1240007 · Sherwood Park, Canada
    • Investigational Site Number: 1520003 · Santiago, Chile
    • Investigational Site Number: 1520002 · Santiago, Chile
    • Investigational Site Number: 1520001 · Santiago, Chile
    • Investigational Site Number: 1520005 · Santiago, Chile
    • Investigational Site Number: 2030002 · Ostrava, Czechia
    • Investigational Site Number: 2030003 · Ostrava, Czechia
    • Investigational Site Number: 2030001 · Prague, Czechia
    • Investigational Site Number: 2030004 · Prague, Czechia
    • Investigational Site Number: 2500001 · Antony, France
    • Investigational Site Number: 2500004 · Bezannes, France
    • Investigational Site Number: 2500007 · Toulouse, France
    • Site Number: 3480001 · Debrecen, Hungary
    • Investigational Site Number: 3480003 · Pécs, Hungary
    • Investigational Site Number: 3760002 · Jerusalem, Israel
    • Investigational Site Number: 3760001 · Tel Aviv, Israel
    • Investigational Site Number: 3800002 · Milan, Italy
    • Istituto Dermatologico San Gallicano, IRCCS - Site Number : 3800004 · Roma, Italy
    • Meiwa Hospital · Nishinomiya, Japan
    • University of the Ryukyus Hospital - Site Number: 3920002 · Nishihara, Japan
    • Nihon University Itabashi Hospital · Tokyo, Japan
    • …and 9 more on the registry record
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07170917
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 12, 2025
Start date
Nov 6, 2025
Primary completion
Feb 9, 2027 (estimated)
Completion
Nov 23, 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
contact-us@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivekimig

Start the discussion